Update on cholinergic drugs in Alzheimer's disease

Drugs of Today

Volumn 32, Issue 7, 1996, Pages 529-537

  Kumar, Vinod ^a   Sugaya, Kiminobu ^a   Saunders, Shawn ^a   Mechanic, Jordan ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ACETYLCHOLINE; BETHANECHOL; CHOLINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GANGLIOSIDE; HEPTYLPHYSOSTIGMINE; METRIFONATE; N METHYL N (1 METHYL 4 PYRROLIDINO 2 BUTYNYL)ACETAMIDE; NERVE GROWTH FACTOR; NICOTINE; OXOTREMORINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; THIOPILOCARPINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DEPRESSION; GASTROINTESTINAL DISEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MEMORY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARANOIA; RASH; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; TREMOR;

EID: 0029729363     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Katzman R. Alzheimer's disease. New Engl J Med 1986, 314: 964-73.
2. Doraiaswany, P.M., Krishman, K.R., Nemeroff, C.B. Neuropeptides and neurotransmitters in Alzheimer's disease. Bailliere Clin Endocrinol Metab 1991, 5 (1 ): 59-76.
3. Perry, E.K., Perry, R.H., Tomlinson, B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977, 1: 189.
4. Davies, P., Maloney, A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2: 1403.
5. Francis, P.T., Palmer, A.M., Sioms, N.R. et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. Lancet 1985, 4: 7-11.
6. Kumar, V., Peterson, K., Kumar, R. Cholinergic drugs in Alzheimer's disease: Past, present, future. In: Treating Alzheimer's and Other Dementias. Bergener, M., Finkel, S.I. (Eds). Springer Publishing Co.: New York 1995, 484-95.
7. Perry, E.K., Tomlinson, B.E., Blessed, G. et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2: 1457-9.
8. Bluszlajn, J.K., Liscovitch, M., Richardson, U.I. Synthesis of acetylcholine from choline derived phosphatidylcholine in a human neuronal cell line. Proc Natl Acad Sci USA 1987, 84: 5474-7.
9. Wurtman R.S., Bluszlajn, J.K., Maire, J.C. Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease. Neurochem Int 1985, 7: 369-75.
10. Ferris, S.H., Reisberg, B., Crook, R. et al. Pharmacologic treatment of senile dementia: Choline, L-dopa, piracetam, and choline plus piracetam. In: Alzheimer's Disease: A Report of Progress. Aging, Vol. 19. Corkin, S., Davis, K.L., Growdon, J.H., Usdin, E., Wurtman, R.J. (Eds.). Raven Press: New York 1982.
11. Signoret, J.L., Whitely, A., Lhermitte, F. Influence of choline on amnesia in early Alzheimer's disease. Lancet 1978, 14: 837.
12. Fovall, P., Dysken, M.W., Lazarus, L.W. et al. Choline bitartrate treatment of Alzheimer's type dementia. Commun Psychopharmacol 1980, 4: 141-5.
13. Etienne, P., Gauthier, S., Johnson, G. et al. Clinical effects of choline in Alzheimer's disease. Lancet 1978, 4: 508-9.
14. Smith, C.M., Swash, M., Exton-Smith, A.N., Phillips, M.J., Overstall, P.W., Piper, M.E. Choline therapy in Alzheimer's disease. Lancet 1978, 5: 318.
15. Peters, B.H., Levin, H. Effects of physostigmine and lecithin on memory in Alzheimer's disease. Ann Neurol 1979, 6: 219-21.
16. Kaye, W.H., Sitaram, H., Weingartner, M.H., Ebert, M.H., Smallberg, S., Gillin, J.C. Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment. Biol Psychiatry 1982, 17: 275-80.
17. Pomara, N., Domino, E.F., Yoon, H., Brinkman, S., Tamminga, C.A., Gershon, S. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. J Clin Psychiatry 1983, 44: 203-95.
18. Vroulis, G.A., Smith, R.C., Brinkman, S., Schoolar, J., Gordon, J. The effects of lecithin on memory in patients with senile dementia of the Alzheimer's type. Psychopharmacol Bull 1981, 17: 127-8.
19. Domino, E.F., Monor, L., Duff, I.F., Tait, S., Gershon, S. Effects of oral lecithin on blood choline levels and memory tests in geriatric volunteers. In: Alzheimer's Disease: A Report of Progress. Aging, Vol. 19. Corkin, S., Davis, K.L., Growdon, J.H., Usdin, E., Wurtman, R.J. (Eds.). Raven Press: New York 1982.
20. Little, A., Levy, R., Chuaqui-Kidd, P., Hand, D. A double-blind placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neural Neurosurg Psychiatry 1985, 48: 736-42.
21. Giacobini, E. Pharmacotherapy of Alzheimer disease: New drugs and novel strategies. Prog Brain Res 1993, 98: 447-54.
22. Thai, L.J., Masur, D.M., Sharpless, N.S., Fuld, P.A., Davies, P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Neuropsychopharmacol Biol Psychiatry 1986, 10: 627-36.
23. Muramoto, O., Sugishita, M., Ando, K. Cholinergic system and constructural praxis. A further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984, 47: 485-91.
24. Mayeux, R., Albert, M., Jenike, M. Physostigmine-induced myoclonus in alzheimer's disease. Neurology 1987, 37: 345-6.
25. Thai, L.J., Masur, D.M., Blau, A.D., Fuld, P.A., Klauber, M.R. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Amer Geriat Soc 1989, 37: 42-8.
26. Beller, S.A., Overall, J.E., Rhoades, H.M., Swann, A.C. Long-term outpatient treatment of senile dementia with oral physostigmine. J Clin Psychiatry 1988, 49: 400-4.
27. Peters, B.H., Levin, H.S. Chronic oral physostigmine and lecithin administration in memory disorders of aging. In: Alzheimer's Disease: A Report of Progress. Aging, Vol. 19. Corkin, S., Davis, K.L., Growdon, J.H., Usdin, E., Wurtman, R.J. (Eds). Raven Press: New York 1982.
28. Stern, Y., Sano, M., Mayeux, R. Long-term administration of physostigmine in Alzheimer's disease. Neurology 1988, 38: 1837-41.
29. Bajada, S. A trial of choline chloride and physostigmine in Alzheimer's dementia. In: Alzheimer's Disease: A Report of Progress. Aging, Vol. 19. Corkin S., Davis, K.L., Growdon, J.W., Usdin, E., Wurtman, R.J. (Eds.). Raven Press: New York 1982.
30. Caltagirone, C., Gainotti, G., Masullo, C. Oral administration of chronic physostigmine does not improve cognitive or amnesic performances in Alzheimer's presenile dementia. J Neurosci 1982, 16: 247-9.
31. Wettstein, A. No effect from double-blind trial of physostigmine and lecithin in Alzheimer's disease. Arch Neurol 1983, 13: 210-2.
32. Kumar, V., Caleche, P. Treatment of Alzheimer's disease with cholinergic drugs. Int J Clin Pharmacol Ther Toxicol 1991, 29: 25-37.
33. Davis, K.L., Mohs, R.C., Tinklenberg, J.R. Enhancement of memory by physostigmine. New Engl J Med 1979, 301: 946.
34. Davis, K.L., Mohs, R.C. Enhancement of memory process in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982, 139: 1421-4.
35. Sullivan, E.V., Shedlack, K.J., Corkin, S., Growdon, J.H. Physostigmine and lecithin in Alzheimer's disease. In: Alzheimer's Disease: A Report of Progress. Aging, Vol. 19. Corkin, S., Davis, K.L., Growdon, J.H., Usdin, E., Wurtman, R.J. (Eds). Raven Press: New York 1982.
36. Johns, C.A., Haroutunian, V., Greenwald, B.S. et al. Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Dev Res 1985, 5: 77-96.
37. Christie, J.E., Shering, A., Ferguson, J., Phil, M., Glen, A.M. Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981, 138: 46-50.
38. Elbe, R.J., Giacobini, E., Becker, R.E. Treatment of Alzheimer dementia with steady-state infusion of physostigmine. In: Current Research in Alzheimer's Therapy. Giacobini, E., Becker, R. (Eds.). Taylor and Francis: New York 1988.
39. Smith, C.M., Swash, M. Physostigmine in Alzheimer's disease. Lancet 1979, 1: 42.
40. Muramoto, O., Sugishita, M., Sugita, H., Tayokura, Y. Effect of physostigmine on constructural and memory tasks in Alzheimer's disease. Arch Neurol 1979, 36: 501-3.
41. Smith, C.M., Semple, S.A., Swash, M. Effects of physostigmine on responses in memory tests in patients with Alzheimer's disease. In: Alzheimer's Disease: A Report of Progress. Aging, Vol. 19. Corkin, S., Davis, K.L., Growdon, J.H., Usdin, E., Wurtman, R.J. (Eds). Raven Press: New York 1982.
42. Schwartz, A.S., Kohlstaedt, E.V. Physostigmine effects in Alzheimer's disease. Relationship to dementia severity. Life Sci 1986, 38: 1021-8.
43. Summers, W.K., Viesselman, J.O., Marsh, G.M., Candelora, K. Use of THA in treatment of Alzheimer-like dementia: Pilot study in twelve patients. Biol Psychiatry 1981, 16: 145-53.
44. Gauthier, S., Masson, H., Gauthier, L. et al. Tetrahydroaminoacridine and lecithin in Alzheimer's disease. In: Current Research in Alzheimer's Therapy. Giacobini, E., Becker, R. (Eds). Taylor and Francis: New York 1988
45. Summers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K., Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 1986, 315: 1241-5.
46. Fitten, L.J., Perryman, K.M., Gross, P., Steinberg, A. Chronic oral THA administration in mice, monkeys, and man. Int Symp Adv Alzheimer Ther: Cholinesterase Inhibitors 1988.
47. Fitten, L.J., Perryman, K.M., Sims, P.L., Gross, P.L., Cummins, J., Marshall, C. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: A double-blind study. Am J Psychiatry 1990, 147: 239-41.
48. Chattellier, G., Lacomblez, L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer's type: A multicenter trial. Br Med J 1990, 300: 495-9.
49. Knapp, M.J., Knupman, D.S., Solomon, P.R. et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994, 271: 985.
50. Kumar, V. Efficacy and side effects of THA in Alzheimer's disease patients. In: Current Research in Alzheimer's Therapy. Giacobini, E., Becker, R. (Eds.). Taylor and Francis: New York 1988.
51. Kumar, V., Becker, R.E. Clinical pharmacology of tetrahydroaminoacridine: A possible therapeutic agent for Alzheimer's disease. Int J Clin Pharmacol Ther Toxicol 1989, 27: 478-85.
52. Rogers, S.L., Doody, R., Mohs, R., Friedhoff, L.T. and the E2020 study team. E2020 (donepezil) improves global and cognitive function in patients with Alzheimer's disease.
53. Gauthier, S., Bouchard, R., Lamontagne, A. et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. New Engl J Med 1990, 322: 1272-6.
54. Buckley, N.J., Bonner, T.I., Buckley, C.M, Brann, M.R. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 1989, 35(41: 469-76.
55. Schroder, H., Giacobini, E., Struble, R.G. et al. Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease. Brain Res Bull 1991, 27(5): 631-6.
56. 1 muscarinic receptors to G protein in Alzheimer's disease. Alzheimer's Dis Assoc Disord 1991, 5 (3): 1631-72.
57. Hollander, E., Davidson, M., Mohs, R.C. et al. RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects. Biol Psychiatry 1987, 22: 1067-78.
58. Bruno, G., Mohr, E., Gillespie, M., Fedio, P., Chase, T.N. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Arch Neurol 1986, 43: 659-61.
59. Harbaugh, R.E., Roberts, D W., Coombs, D.W., Saunders, R.L., Reeder, T.M. Preliminary report: Intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 1984, 15: 514-8.
60. Read, S. Intra-cerebro-ventricular bethanechol. Dose and response. In: Current Research in Alzheimer's Therapy. Giacobini, E., Becker, R. (Eds), Taylor and Francis: New York 1988.
61. Sugaya, K., Giacobini, E., Chiappinelli, V.A. Mcotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease. J Neurosci Res 1990, 27 (3): 349-59.
62. Whitehouse, P.J., Martino, A.M., Antuono, P.G. et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986, 371 (1): 146-51.
63. Nakayama, H., Okuda, H., Nakashima, T. Molecular diversity and properties of brain nicotinic acetylcholine receptor. Folia Pharmacol Jpn 1994, 104 (3): 241-9.
64. Newhouse, P.A., Sunderland, T., Narang, P.K. et al. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in non-smoking healthy volunteers and in patients with Alzheimer's disease. Psychopharmacology 1990, 95 (2): 171-5.
65. Hellweg, R., Fischer, W., Hock, C., Gage, F.H., Bjorklund, A., Thoenen, H. Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments. Brain Res 1990, 537 (1-2): 123-30.
66. Fischer, W., Wictorin, K., Bjorklund, A., Williams, L.R., Varon, S., Gage, F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987, 329: 65-8.
67. Seiger, A., Nordberg, A., von Holst, H. et al. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav Brain Res 1993, 57 (2): 255-61.